The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
A
Anneliene H. Jonker
E
Elena-Alexandra Tataru
H
Holm Graessner
D
David Dimmock
A
Adam Jaffe
G
Gareth Baynam
J
James Davies
S
Shruti Mitkus
O
Oxana Iliach
R
Rich Horgan
E
Erika F. Augustine
A
Alison Bateman-House
A
Anna Maria Gerdina Pasmooij
T
Tim Yu
M
Matthis Synofzik
J
Julie Douville
L
Larissa Lapteva
P
Philip John Brooks
D
Daniel O’Connor
A
Annemieke Aartsma-Rus
Article Details
Journal
Nature Reviews Drug Discovery
Volume / Issue
Vol. 24, Issue 1
Published
January 01, 2025
Pages
40-56
ISSN
1474-1776
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Drug Discovery
Springer Science and Business Media LLC
ISSN: 1474-1776 Q1 Medicine
Authors (20)
A
Anneliene H. Jonker
E
Elena-Alexandra Tataru
H
Holm Graessner
D
David Dimmock
A
Adam Jaffe
G
Gareth Baynam
J
James Davies
S
Shruti Mitkus
O
Oxana Iliach
R
Rich Horgan
E
Erika F. Augustine
A
Alison Bateman-House
A
Anna Maria Gerdina Pasmooij
T
Tim Yu
M
Matthis Synofzik
J
Julie Douville
L
Larissa Lapteva
P
Philip John Brooks
D
Daniel O’Connor
A
Annemieke Aartsma-Rus
Related Articles from this Journal
Can multispecific biologics break the efficacy ceiling?
Asher Mullard
Jul 2026
10.1038/d41573-026-00106-5
Novel drug targets in 2025
Sorin Avram, Liliana Halip et al.
Jul 2026
10.1038/d41573-026-00102-9
The unglamourous AI wins that are quietly transforming drug discovery and development
Asher Mullard
Jul 2026
10.1038/d41573-026-00099-1
Upcoming FDA approval decisions in Q3 2026
Swetha Kota
Jul 2026
10.1038/d41573-026-00103-8
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Asher Mullard
Jul 2026
10.1038/d41573-026-00101-w